<DOC>
	<DOCNO>NCT00619346</DOCNO>
	<brief_summary>This phase 1 study establish safety tolerability profile pafuramidine maleate 100 mg BID administer orally 14 day healthy subject</brief_summary>
	<brief_title>Randomized , Double-Blind Phase 1 Safety Tolerability Study Pafuramidine Maleate ( DB289 ) Healthy Subjects</brief_title>
	<detailed_description>This Phase 1 , randomize , double-blind , placebo-controlled , parallel treatment single center safety tolerability study . Subjects meet inclusion criterion none exclusion criterion randomize 4:1 fashion receive either pafuramidine maleate 100 mg tablet match placebo tablet administer twice daily 14 day .</detailed_description>
	<mesh_term>Maleic acid</mesh_term>
	<criteria>1 . Healthy male female volunteer minimum 18 year 75 year age 2 . Female must nonlactating either nonchildbearing potential ( i.e . sterilize via hysterectomy bilateral tubal ligation ) childbearing potential , must negative human chorionic gonadotropin ( hCG ) pregnancy test practice effective dual barrier contraceptive method consent 42 day initiation study drug administration . 3 . Negative test hepatitis B surface antigen , Hepatitis C antibody HIV 1 2 antibody within 14 day prior admission study 4 . The subject provide write informed consent prior admission study . 1 . History clinically relevant medical illness Investigator opinion may jeopardize subject safety interfere participation study , include limited hemoglobinopathy , hemophilia , clinically significant retinal abnormality , liver disease , chronic pulmonary disease , significant cardiovascular disease , diabetes , thyroid disease , gout , psychiatric psychological disorder , CNS trauma active seizure disorder , allergic immunologicallymediated disorder 2 . History drug alcohol abuse , ( * 10 drink weekly ) 3 . Blood donation within 30 day prior dose 4 . History drug allergy , anaphylaxis laryngeal edema 5 . Use medication within 7 day dose study medication anticipate need medication study conduct 6 . Use investigational medication within 6 week prior dose study medication schedule receive investigational drug pafuramidine maleate course study 7 . Clinically significant abnormal laboratory value screen include CBC , blood chemistry urinalysis 8 . Clinically significant anomaly note physical examination ECG 9 . Resting pulse rate &gt; 100 beat per minute &lt; 45 beat per minute screening period , either supine standing . 10 . Any condition , compromise ability give inform consent communicate Investigator require completion study 11 . The subject previously enrol study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>Safety</keyword>
	<keyword>Tolerability</keyword>
	<keyword>Assessment potential adverse event and/or laboratory abnormality</keyword>
</DOC>